Scientists Identify Link between Inflammation and Type 2 Diabetes

Researchers Identify Link between Inflammation and Type 2 Diabetes

A newly published study led by Yale University reveals the molecular mechanism by which insulin normally inhibits production of glucose by the liver and why this process stops working in patients with type 2 diabetes, leading to hyperglycemia.

The findings are published February 5 in the journal Cell.

“In the study, we set out to examine how insulin normally works to turn off production of glucose by the liver and why this process goes awry in patients with type 2 diabetes,” said Gerald I. Shulman, the George R. Cowgill professor of physiological chemistry, professor of medicine and cellular & molecular physiology at Yale School of Medicine, and an investigator with the Howard Hughes Medical Institute.

Experts have long debated how insulin suppresses glucose production by the liver. Many have asserted that insulin’s suppression of glucose production was due to the direct action of insulin on the liver. But the Yale-led team uncovered a different process that challenges current theories and may lead to new targets for treatment.

Yale researchers hypothesized that insulin suppressed glucose production by the liver by inhibiting the breakdown of fat, which would result in a reduction in hepatic acetyl CoA, a key molecule that they showed was critical in regulating the conversion of amino acids and lactate to glucose. They also found that reversal of this process, due to inflammation in adipose (fatty) tissue, led to increased hepatic glucose production and hyperglycemia in high-fat-fed rodents and obese, insulin-resistant adolescents. “These studies identify hepatic acetyl CoA as a key mediator of insulin action on the liver and link it to inflammation-induced hepatic insulin resistance and type 2 diabetes,” Shulman explained.

This new insight into insulin resistance paves the way for exploring new treatments. “None of the drugs we currently use to treat type 2 diabetes target the root cause,” said Shulman. “By understanding the molecular basis for hepatic insulin resistance we now can design better and more effective drugs for its treatment.”

Other authors include Rachel J. Perry, Joao-Paulo G. Camporez, Romy Kursawe, Paul M. Titchenell, Dongyan Zhang, Curtis J. Perry, Michael J. Jurczak, Abudukadier Abulizi, Myoung Sook Han, Xian-Man Zhang, Hai-Bin Ruan, Xiaoyong Yang, Sonia Caprio, Susan M. Kaech, Hei Sook Sul, Morris J. Birnbaum, Roger J. Davis, Gary W. Cline, and Kitt Falk Petersen.

The study was funded by grants from the National Institutes of Health (R01 DK-40936, R24 DK-085638, R01 AG-023686, P30 DK-45735, U24 DK-059635, T32 DK-101019, R01 DK-056886, R01 DK-093959, R01 NS-087568, R01 DK93928, UL1 TR-000142, R01-HD028016, R01-HD 04787, R01 DK085577, R24 DK-090963) and the Novo Nordisk Foundation Center for Basic Metabolic Research.

Publication: Rachel J. Perry, et al, “Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes,” Cell, 2015; doi:10.1016/j.cell.2015.01.012

Image: Yale University

Be the first to comment on "Scientists Identify Link between Inflammation and Type 2 Diabetes"

Leave a comment

Email address is optional. If provided, your email will not be published or shared.